Caris Life Sciences, Inc.

Healthcare · Biotechnology · —

27.50$ -9.7% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Income Statement

Caris Life Sciences, Inc. (CAI) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 264 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement CAI
Line item	Q2 14	Q3 14	Q4 14	Q1 15	Q2 15	Q3 15	Q4 15	Q1 16	Q2 16	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	55	59	59	58	59	66	66	67	72	78	77	82	83	90	94	95	106	115	116	111	106	108	100	105	76	79	64	81	86	101	81	100	102	130	121	181	217	293	216	264	990
Cost of Revenue	19	20	20	21	22	27	53	30	35	48	44	45	44	46	45	48	54	59	58	56	55	56	53	54	29	30	24	42	43	47	55	62	57	59	64	68	69	72	75	84	300
Gross Profit	36	39	38	37	37	39	13	37	37	31	33	36	39	45	49	48	52	57	57	55	51	52	48	51	47	49	41	39	86	54	26	38	44	71	57	114	148	221	141	180	689
Research & Development	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	34	25	28	27	23	25	22	32	5.4	32	91
Selling, General & Administrative	–	–	–	–	–	–	6.1	8.8	8.9	11	6.9	11	9.7	11	11	11	12	13	14	14	12	13	15	12	7.4	6.4	5.9	7.7	10	12	45	41	41	36	53	64	52	57	60	67	235
Total Operating Expenses	13	13	13	14	14	15	14	18	18	20	16	18	16	14	16	15	15	16	18	20	16	17	19	18	14	13	4.7	7.7	35	12	118	-29	105	108	115	96	115	133	136	153	536
Operating Income	23	26	25	23	23	23	-1.7	19	19	11	17	19	23	30	34	33	37	40	39	35	34	34	28	34	33	36	36	49	51	66	-92	67	-61	-37	-58	18	33	88	5.3	27	153
Interest Expense	8.9	9.3	8.3	8.8	9.0	9.0	9.2	10.0	11	11	11	12	12	14	15	17	18	20	23	24	20	20	19	20	18	17	7.0	11	11	–	9.3	14	14	13	13	19	14	11	13	9.2	47
Pre-Tax Income	15	18	19	15	14	14	-12	8.3	4.1	-3.6	1.0	6.0	13	17	21	18	21	23	20	20	16	16	9.2	-4.6	0.5	17	17	37	40	55	-111	-66	-68	-37	-103	-72	24	82	-0.6	-0.6	105
Income Tax Expense	2.0	1.5	2.3	1.3	1.1	1.3	0.6	1.1	0.4	1.8	0.5	0.7	0.0	-0.1	-15	0.7	0.8	1.2	0.2	1.7	1.3	1.2	1.3	-3.3	1.1	1.3	2.4	2.5	1.9	3.7	–	–	–	–	–	–	–	–	-0.1	0.0	–
Net Income	13	16	16	14	13	13	-13	7.2	3.8	-5.4	0.5	5.3	13	18	37	17	20	22	19	19	9.3	-4.7	7.8	-1.3	-0.6	15	14	36	38	51	-111	-66	-68	-37	-103	-72	24	82	-0.5	-0.6	105
EBITDA	44	47	47	45	45	46	45	41	39	38	41	46	52	60	65	64	69	75	75	76	62	66	54	44	63	66	81	77	51	88	-84	-41	-50	-28	-83	-46	43	98	17	15	173

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings